Candace Westgate, DO, MPH, FACOG, MSCP, will review the evolving landscape of multi-cancer early detection (MCED) testing beyond Galleri, with a focus on emerging assays including CancerGuard and Shield MCD. She will discuss the science behind these tests, current evidence, and how they compare in terms of performance, intended use, and clinical applicability.

Dr. Westgate will also explore practical considerations for clinicians, including patient selection, test interpretation, limitations, and ethical implications of MCED screening. This session is designed to help providers critically evaluate new MCED technologies and thoughtfully integrate them into evidence-based, patient-centered care.

Candace Westgate, DO, MPH, FACOG, MSCP, is a board-certified OB/GYN with advanced training in minimally invasive gynecologic surgery, menopause management, and cancer genetics. She holds additional certifications in advanced laparoscopy, ACOG’s Women’s Genomics Counseling Course, and the City of Hope Intensive Course in Hereditary Cancer Risk Assessment. Dr. Westgate earned her Master of Public Health from Tulane University with a focus on program management and maternal and child health. She completed her medical education at Kirksville College of Osteopathic Medicine and her OB/GYN residency at Georgetown University Hospital in Washington, DC. A national leader in early detection and personalized medicine, Dr. Westgate previously served as Medical Director of the Adventist Health AHEAD Program and now leads Personalized Medicine at Community Health. She is passionate about equipping patients with innovative, genomics-informed tools to take charge of their health and detect cancer at its earliest—and most treatable—stages.